Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension

被引：8

作者：

Koo, Rachel ^{[1
]}

Lo, Jennifer ^{[2
]}

Bock, Matthew J. ^{[2
]}

机构：

[1] Loma Linda Univ Childrens Hlth, Dept Pediat, Loma Linda, CA USA

[2] Loma Linda Univ Childrens Hlth, Div Pediat Cardiol, Loma Linda, CA USA

来源：

CARDIOLOGY IN THE YOUNG | 2019年 / 29卷 / 06期

关键词：

Selexipag; infant; prostacyclin; pulmonary hypertension; paediatric;

D O I：

10.1017/S1047951119001082

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Selexipag is an enteral, selective prostacyclin IP receptor agonist approved for pulmonary hypertension in adults. There are few reports of its use in children and none in infants. We report the first transition of an infant (11.5 months, 8.6 kg) from intravenous treprostinil (40 ng/kg/minute) to enteral selexipag (400 mcg twice daily) with a good response and no adverse effects.

引用

页码：849 / 851

页数：3

共 50 条

[1] Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series
Fanous, Sherif M.
Janmohamed, Munir
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (23) : 1877 - 1881
[2] Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
Asuka Furukawa
Yuichi Tamura
Hiroya Iwahori
Masato Goto
Narutaka Ohashi
Teruo Okabe
Akio Kawamura
BMC Pulmonary Medicine, 17
[3] Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
Furukawa, Asuka
Tamura, Yuichi
Iwahori, Hiroya
Goto, Masato
Ohashi, Narutaka
Okabe, Teruo
Kawamura, Akio
BMC PULMONARY MEDICINE, 2017, 17
[4] Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution
Yanaka, Kenichi
Guillien, Alicia
Soumagne, Thibaud
Benet, Justin
Piliero, Nicolas
Picard, Francois
Pison, Christophe
Sitbon, Olivier
Bouvaist, Helene
Degano, Bruno
EUROPEAN RESPIRATORY JOURNAL, 2020, 55 (06)
[5] Transition from parenteral to oral treprostinil in pulmonary arterial hypertension
Chakinala, Murali M.
Feldman, Jeremy P.
Rischard, Franz
Mathier, Michael
Broderick, Meredith
Leedom, Nicole
Laliberte, Kevin
White, R. James
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (02) : 193 - 201
[6] Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension
Corboz, Michel R.
Plaunt, Adam J.
Malinin, Vladimir S.
Li, Zhili
Gauani, Helena
Chun, Donald
Cipolla, David
Perkins, Walter R.
Chapman, Richard W.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2022, 383 (01) : 103 - 116
[7] Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry
Lachant, D.
Minkin, R.
Swisher, J.
Mogri, M.
Zolty, R.
Hwang, S.
Seaman, S.
Broderick, M.
Sahay, S.
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2023, 82
[8] Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension
Reisbig, KA
Coffman, PA
Floreani, AA
Bultsma, CJ
Olsen, KM
ANNALS OF PHARMACOTHERAPY, 2005, 39 (04) : 739 - 743
[9] Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study
Frost, Adaani
Janmohamed, Munir
Fritz, Jason S.
McConnell, John W.
Poch, David
Fortin, Terry Ann
Miller, Chad E. g
Chin, Kelly M.
Fisher, Micah
Eggert, Michael
McEvoy, Colleen
Benza, Raymond L.
Farber, Harrison W.
Kim, Nick H.
Pfister, Thomas
Shiraga, Yoko
McLaughlin, Vallerie
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (01) : 43 - 50
[10] Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension
Olsson, Karen M.
Richter, Manuel J.
Kamp, Jan C.
Gall, Henning
Heine, Alexander
Ghofrani, Hossein-Ardeshir
Fuge, Jan
Ewert, Ralf
Hoeper, Marius M.
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (07) : 748 - 756

← 1 2 3 4 5 →